New Regulatory Framework for Medical Devices in Japan: Current Regulatory Considerations Regarding Clinical Studies |
| |
Authors: | Akihide Konishi Soichiro Isobe Daisaku Sato |
| |
Institution: | 1. Office of Medical Device III, Pharmaceuticals and Medical Devices Agency, 3-2-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013, Japan;2. Compliance and Narcotics Division, Pharmaceutical Safety and Environmental Health Bureau, Ministry of Health, Labour and Welfare, Tokyo, Japan;3. Pharmaceutical Safety Division, Pharmaceutical Safety and Environmental Health Bureau, Ministry of Health, Labour and Welfare, Tokyo, Japan |
| |
Abstract: | In Japan, a recent issue that required an urgent response was the streamlining of regulations concerning clinical trials of medical devices. On July 31, 2017, the Ministry of Health, Labour and Welfare enacted a new regulatory framework called the fast-break scheme for innovative medical devices aiming to expedite patient access while reducing the premarket regulatory burden of clinical trials and enhancing postmarketing commitments. The new framework is expected to provide greater benefits to patients who require access to new medical devices and to companies via improved transparency and predictability, as well as to reduce the social and medical cost incurred for medical innovation. |
| |
Keywords: | FDA Food and Drug Administration MHLW Ministry of Health Labour and Welfare PMDA Pharmaceuticals and Medical Devices Agency |
本文献已被 ScienceDirect 等数据库收录! |
|